Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796242 | 0.89 | PKM (0.44) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL13034088 | 0.85 | HSD17B10 (0.45) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL28788679 | 0.85 | HSD17B10 (0.39) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL9731794 | 0.83 | HSD17B10 (0.46) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL19683552 | 0.81 | ALDH1A1 (0.44) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL1315783 | 0.81 | NOTUM (0.40) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL28773420 | 0.79 | HSD17B10 (0.41) | HSD17B10KDM4EALDH1A1CYP3A4NPSR1 | |
| SCHEMBL29606534 | 0.79 | HSD17B10 (0.41) | HSD17B10KDM4EALDH1A1CYP3A4NPSR1 | |
| SCHEMBL14850042 | 0.78 | PKM (0.41) | HSD17B10KDM4EPKMALDH1A1CYP3A4 | |
| SCHEMBL21713935 | 0.77 | FFAR4 (0.44) | HSD17B10KDM4EPKMALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2048153-A1 | SUBSTITUTED SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | SLC5A1, OR10J3, AKR1C3 | HSD17B10 699/4885KDM4E 1118/4885PKM 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.